- Home
- KPRX vs INTS Comparison
KPRX vs INTS Comparison
Compare KPRX & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- INTS
- Stock Information
- Founded
- KPRX 1998
- INTS 2012
- Country
- KPRX United States
- INTS United States
- Employees
- KPRX N/A
- INTS N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- INTS Health Care
- Exchange
- KPRX Nasdaq
- INTS Nasdaq
- Market Cap
- KPRX 9.1M
- INTS 9.4M
- IPO Year
- KPRX N/A
- INTS 2023
- Fundamental
- Price
- KPRX $2.82
- INTS $0.31
- Analyst Decision
- KPRX Strong Buy
- INTS Strong Buy
- Analyst Count
- KPRX 1
- INTS 3
- Target Price
- KPRX $10.00
- INTS $8.50
- AVG Volume (30 Days)
- KPRX 1.4M
- INTS 2.4M
- Earning Date
- KPRX 08-08-2025
- INTS 08-07-2025
- Dividend Yield
- KPRX N/A
- INTS N/A
- EPS Growth
- KPRX N/A
- INTS N/A
- EPS
- KPRX N/A
- INTS N/A
- Revenue
- KPRX $20,000.00
- INTS N/A
- Revenue This Year
- KPRX N/A
- INTS N/A
- Revenue Next Year
- KPRX N/A
- INTS N/A
- P/E Ratio
- KPRX N/A
- INTS N/A
- Revenue Growth
- KPRX N/A
- INTS N/A
- 52 Week Low
- KPRX $2.51
- INTS $0.26
- 52 Week High
- KPRX $4.86
- INTS $5.10
- Technical
- Relative Strength Index (RSI)
- KPRX 40.86
- INTS 37.14
- Support Level
- KPRX $2.87
- INTS $0.26
- Resistance Level
- KPRX $3.22
- INTS $0.35
- Average True Range (ATR)
- KPRX 0.18
- INTS 0.05
- MACD
- KPRX -0.03
- INTS 0.02
- Stochastic Oscillator
- KPRX 21.20
- INTS 9.36
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.